Article

Square-edge design of lens effective against PCO

Washington, DC—The three-piece square-edge design of the Tecnis IOL platform (AMO) seems to protect the eye against development of posterior capsular opacification (PCO) by preventing migration of epithelial cells for at least 3 years after implantation, reported Michael Colvard, MD, FACS, at the annual meeting of the American Society of Cataract and Refractive Surgery.

Washington, DC-The three-piece square-edge design of the Tecnis IOL platform (AMO) seems to protect the eye against development of posterior capsular opacification (PCO) by preventing migration of epithelial cells for at least 3 years after implantation, reported Michael Colvard, MD, FACS, at the annual meeting of the American Society of Cataract and Refractive Surgery.

The Tecnis Edge is a continuous 360° square-edge configuration that has a "barrier effect," uninterrupted by haptic insertion.

In the cases under discussion, Dr. Colvard pointed out that he attempted to make all the anterior capsulotomies central in location and 4 mm in diameter and he used bimanual irrigation/aspiration for cortical cleanup. All the posterior capsules were polished, and the anterior capsules were not.

In this study, 29 patients had the Tecnis three-piece silicone IOL platform implanted between August and December 2001. Dr. Colvard and colleagues conducted a retrospective review of the rates of YAG capsulotomy in patients who had a minimal follow-up of 3 years. A prospective evaluation of the PCO was done using slit-lamp examination and digital retroillumination photography, using the EPCO 2000 analysis system.

Capsular changes demonstrated on retroillumination photos are graded on a scale from 0 to 4 as follows: 0, crystal clear; 1 (minimal), mild wrinkling of the capsule, mild homogeneous layers or sheets of lens epithelium cells; 2 (mild), honeycomb patterns of PCO, thicker homogeneous layers, denser fibrosis; 3 (moderate), classical Elschnig pearls, very thick homogeneous layer; and 4 (severe), very thick Elschnig pearls with a "darkening effect," any type of severe opacification.

No YAG capsulotomies Three-year clinical data were obtained for the 29 patients. Of these, 23 patients were examined 3 years after implantation at the Colvard Eye Center, and six patients, who were not available for examination, were interviewed by telephone. None of the patients had required a YAG posterior capsulotomy.

"To maintain consistency with previous publications, we looked at PCO values for the entire optic and the central 3-mm zone. The averaged PCO values demonstrated virtually no capsular opacification over the area of the entire optic or none whatsoever of the central 3-mm zone," Dr. Colvard explained.

Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
Image credit: Ophthalmology Times; EnVision Summit 2025: Sonia H. Yoo, MD, shares what to expect from the cataract and refractive agenda
© 2025 MJH Life Sciences

All rights reserved.